299 related articles for article (PubMed ID: 35332124)
1. Ultrasound-controllable engineered bacteria for cancer immunotherapy.
Abedi MH; Yao MS; Mittelstein DR; Bar-Zion A; Swift MB; Lee-Gosselin A; Barturen-Larrea P; Buss MT; Shapiro MG
Nat Commun; 2022 Mar; 13(1):1585. PubMed ID: 35332124
[TBL] [Abstract][Full Text] [Related]
2. Spatiotemporal control of engineered bacteria to express interferon-γ by focused ultrasound for tumor immunotherapy.
Chen Y; Du M; Yuan Z; Chen Z; Yan F
Nat Commun; 2022 Aug; 13(1):4468. PubMed ID: 35918309
[TBL] [Abstract][Full Text] [Related]
3. Engineering bacteria for cancer immunotherapy.
Zalatan JG; Petrini L; Geiger R
Curr Opin Biotechnol; 2024 Feb; 85():103061. PubMed ID: 38219524
[TBL] [Abstract][Full Text] [Related]
4. Engineering bacteria as interactive cancer therapies.
Gurbatri CR; Arpaia N; Danino T
Science; 2022 Nov; 378(6622):858-864. PubMed ID: 36423303
[TBL] [Abstract][Full Text] [Related]
5. A synthetic biology approach to engineering circuits in immune cells.
Hoces D; Miguens Blanco J; Hernández-López RA
Immunol Rev; 2023 Nov; 320(1):120-137. PubMed ID: 37464881
[TBL] [Abstract][Full Text] [Related]
6. Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy.
Chen J; Li T; Liang J; Huang Q; Huang JD; Ke Y; Sun H
Biomed Pharmacother; 2022 Jan; 145():112443. PubMed ID: 34847476
[TBL] [Abstract][Full Text] [Related]
7. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Brempelis KJ; Cowan CM; Kreuser SA; Labadie KP; Prieskorn BM; Lieberman NAP; Ene CI; Moyes KW; Chinn H; DeGolier KR; Matsumoto LR; Daniel SK; Yokoyama JK; Davis AD; Hoglund VJ; Smythe KS; Balcaitis SD; Jensen MC; Ellenbogen RG; Campbell JS; Pierce RH; Holland EC; Pillarisetty VG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115946
[TBL] [Abstract][Full Text] [Related]
8. Engineered bacteria in tumor immunotherapy.
Chen H; Zhu Y; Zhang C; Hu L; Yang K
Cancer Lett; 2024 May; 589():216817. PubMed ID: 38492769
[TBL] [Abstract][Full Text] [Related]
9. Programmable bacteria induce durable tumor regression and systemic antitumor immunity.
Chowdhury S; Castro S; Coker C; Hinchliffe TE; Arpaia N; Danino T
Nat Med; 2019 Jul; 25(7):1057-1063. PubMed ID: 31270504
[TBL] [Abstract][Full Text] [Related]
10. Engineering Diagnostic and Therapeutic Gut Bacteria.
Landry BP; Tabor JJ
Microbiol Spectr; 2017 Oct; 5(5):. PubMed ID: 29052539
[TBL] [Abstract][Full Text] [Related]
11. Tweak to Treat: Reprograming Bacteria for Cancer Treatment.
Sieow BF; Wun KS; Yong WP; Hwang IY; Chang MW
Trends Cancer; 2021 May; 7(5):447-464. PubMed ID: 33303401
[TBL] [Abstract][Full Text] [Related]
12. Mechanogenetics for the remote and noninvasive control of cancer immunotherapy.
Pan Y; Yoon S; Sun J; Huang Z; Lee C; Allen M; Wu Y; Chang YJ; Sadelain M; Shung KK; Chien S; Wang Y
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):992-997. PubMed ID: 29343642
[TBL] [Abstract][Full Text] [Related]
13. Advancements in synthetic biology-based bacterial cancer therapy: A modular design approach.
Arboleda-García A; Alarcon-Ruiz I; Boada-Acosta L; Boada Y; Vignoni A; Jantus-Lewintre E
Crit Rev Oncol Hematol; 2023 Oct; 190():104088. PubMed ID: 37541537
[TBL] [Abstract][Full Text] [Related]
14. The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering.
Dailey KM; Allgood JE; Johnson PR; Ostlie MA; Schaner KC; Brooks BD; Brooks AE
Future Microbiol; 2021 Mar; 16(5):341-368. PubMed ID: 33754804
[TBL] [Abstract][Full Text] [Related]
15. Progress of engineered bacteria for tumour therapy.
Xia X; Zhang JW; Zhao B; Zhang M; Chen ZR; Zhang BF; Ji YL; Wang X; Xiong WM; Li JW; Lv QL
Int Immunopharmacol; 2024 May; 132():111935. PubMed ID: 38599096
[TBL] [Abstract][Full Text] [Related]
16. Current advances in bacteria-based cancer immunotherapy.
Guo C; Liu J; Zhang Y
Eur J Immunol; 2024 Feb; 54(2):e2350778. PubMed ID: 38105295
[TBL] [Abstract][Full Text] [Related]
17. Spatiotemporally Controllable Distribution of Combination Therapeutics in Solid Tumors by Dually Modified Bacteria.
Wang L; Cao Z; Zhang M; Lin S; Liu J
Adv Mater; 2022 Jan; 34(1):e2106669. PubMed ID: 34687102
[TBL] [Abstract][Full Text] [Related]
18. Synthetic biology in cell-based cancer immunotherapy.
Chakravarti D; Wong WW
Trends Biotechnol; 2015 Aug; 33(8):449-61. PubMed ID: 26088008
[TBL] [Abstract][Full Text] [Related]
19. Bacteria-Based Cancer Immunotherapy.
Huang X; Pan J; Xu F; Shao B; Wang Y; Guo X; Zhou S
Adv Sci (Weinh); 2021 Apr; 8(7):2003572. PubMed ID: 33854892
[TBL] [Abstract][Full Text] [Related]
20. Using nanoparticles for
Gorbet MJ; Singh A; Mao C; Fiering S; Ranjan A
Int J Hyperthermia; 2020 Dec; 37(3):18-33. PubMed ID: 33426995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
